Clinical Trial Update: A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 open-label dose-escalation trial evaluating INCB050465 and itacitinib in previously treated B-cell malignancies; study completed with results posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Malignancies

Drugs mentioned

• INCB050465
• Itacitinib (itacitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: B-Cell Malignancies | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-06-28